Metformina reduce efectos adversos de glucocorticoides

Treatment With Metformin May Help Minimize Some Metabolic Complications, Improve Clinical Outcomes For Patients Taking Systemic Glucocorticoid Therapy, Phase 2 Study Suggests

Medwire News (2/26, Barnard) reports researchers conducting a "proof-of-concept phase 2 study suggest that treatment with the antidiabetes drug metformin could help minimize some metabolic complications and improve clinical outcomes for patients taking systemic glucocorticoid therapy" for rheumatic disease, lupus, or asthma. Included in the trial were "53 participants without diabetes treated for an inflammatory disease with continuous prednisolone (≥20 mg/day for ≥4 weeks and ≥10 mg/day for the following 12 weeks, or cumulative dose-equivalent)." Participants were randomized "to receive an escalating dose of oral metformin (850 mg/day on days 1–5, 850 mg twice daily on days 6–10, and 850 mg three times daily thereafter) or placebo for 12 weeks." The findings were published online in The Lancet Diabetes & Endocrinology.

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.